BR112015014092A2 - administração oral transmucosal de acetato de glatirâmer - Google Patents

administração oral transmucosal de acetato de glatirâmer

Info

Publication number
BR112015014092A2
BR112015014092A2 BR112015014092A BR112015014092A BR112015014092A2 BR 112015014092 A2 BR112015014092 A2 BR 112015014092A2 BR 112015014092 A BR112015014092 A BR 112015014092A BR 112015014092 A BR112015014092 A BR 112015014092A BR 112015014092 A2 BR112015014092 A2 BR 112015014092A2
Authority
BR
Brazil
Prior art keywords
glatiramer acetate
oral administration
percent
transmucosal oral
film composition
Prior art date
Application number
BR112015014092A
Other languages
English (en)
Inventor
Huber Gerald
Buerger Martina
Stefan Ralph
Schweizer Stephan
Pries Tanja
Geister Ursula
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of BR112015014092A2 publication Critical patent/BR112015014092A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo “administração oral transmucosal de acetato de glatirâmer” a presente invenção proporciona um curativo oral compreendendo: um forro; e uma composição de película no mesmo, a composição de película compreendendo acetato de glatirâmer, numa quantidade de cerca de 10 por cento até cerca de 40 por cento em peso da composição de película e um ou mais agentes de formação de película numa quantidade total de cerca de 40 por cento a cerca de 80 por cento, em peso, da composição da película.
BR112015014092A 2012-12-21 2013-12-20 administração oral transmucosal de acetato de glatirâmer BR112015014092A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261745243P 2012-12-21 2012-12-21
PCT/US2013/077041 WO2014100643A1 (en) 2012-12-21 2013-12-20 Oral transmucosal delivery of glatiramer acetate

Publications (1)

Publication Number Publication Date
BR112015014092A2 true BR112015014092A2 (pt) 2017-07-11

Family

ID=50979258

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015014092A BR112015014092A2 (pt) 2012-12-21 2013-12-20 administração oral transmucosal de acetato de glatirâmer

Country Status (15)

Country Link
US (1) US20150328277A1 (pt)
EP (1) EP2934493A4 (pt)
JP (1) JP2016503066A (pt)
KR (1) KR20150111919A (pt)
CN (1) CN104869984A (pt)
AU (1) AU2013361057A1 (pt)
BR (1) BR112015014092A2 (pt)
CA (1) CA2895457A1 (pt)
EA (1) EA201591187A1 (pt)
HK (2) HK1214133A1 (pt)
IL (1) IL239279A0 (pt)
MX (1) MX2015007794A (pt)
SG (1) SG11201504461QA (pt)
WO (1) WO2014100643A1 (pt)
ZA (1) ZA201505050B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ609938A (en) 2010-10-11 2015-11-27 Teva Pharma Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
TW201326399A (zh) 2011-10-10 2013-07-01 Teva Pharma 用於預測對格拉替雷（ｇｌａｔｉｒａｍｅｒ）醋酸鹽之臨床反應之單核苷酸多型性之判定
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
US10493122B2 (en) 2014-03-17 2019-12-03 Mapi Pharma Ltd. Sublingual delivery of glatiramer acetate
EP3645029B1 (en) 2017-06-26 2023-01-18 Institut Pasteur Treatments to eliminate hiv reservoirs and reduce viral load

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0679002A (ja) * 1993-12-14 1994-03-22 Hisamitsu Pharmaceut Co Inc 経皮投与用パッチシステム
US6197331B1 (en) * 1997-07-24 2001-03-06 Perio Products Ltd. Pharmaceutical oral patch for controlled release of pharmaceutical agents in the oral cavity
ZA200206457B (en) * 2000-02-18 2003-08-13 Yeda Res & Dev Oral, nasal and pulmonary dosage formulations of copolymer 1.
US20020077278A1 (en) * 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
US20030175328A1 (en) * 2002-03-06 2003-09-18 Adi Shefer Patch for the controlled delivery of cosmetic, dermatological, and pharmaceutical active ingredients into the skin
NZ540318A (en) * 2002-10-31 2007-09-28 Umd Inc Therapeutic compositions for drug delivery to and through covering epithelia
PT1740154E (pt) * 2004-03-12 2009-09-11 Biodel Inc Composições de insulina com absorção melhorada
FI20041425A0 (fi) * 2004-11-05 2004-11-05 Orion Corp Transmukosaalinen veterinäärinen koostumus
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
US20060210616A1 (en) * 2005-03-17 2006-09-21 Linder Barry J Therapeutic patch for ophthalmologic and cosmetic use
US20070021325A1 (en) * 2005-07-21 2007-01-25 Mediplex Corporation Drug formulation containing a solubilizer for enhancing solubility, absorption, and permeability
US20080027011A1 (en) * 2005-12-20 2008-01-31 Hassan Nached Homogeneous paste and gel formulations
KR100809404B1 (ko) * 2005-12-28 2008-03-05 (주)스피어테크 리포좀화 시킨 나노용매를 함유하는 경피흡수 점착시트형 화장료 조성물 및 제조방법
WO2007087188A2 (en) * 2006-01-20 2007-08-02 Merck & Co., Inc. Taste-masked tablets and granules
CA2640243C (en) * 2006-02-17 2015-08-18 Novartis Ag Disintegrable oral films
US20100184848A1 (en) * 2006-07-14 2010-07-22 William Abraham Wine Transdermal formulations of synthetic cannabinoids and nano colloidal silica
CA2671492A1 (en) * 2006-12-04 2008-06-12 The Board Of Trustees Of The University Of Illinois Compositions and methods to treat cancer with cupredoxins and cpg rich dna
EP2161021B1 (en) * 2007-06-07 2017-03-08 Sato Pharmaceutical Co. Ltd. Medicinal film preparation with rapidly dissolving property and flexibility
WO2009005814A2 (en) * 2007-07-03 2009-01-08 Marchitto Kevin S Drug-delivery patch comprising a dissolvable layer and uses thereof
CN101883559B (zh) * 2007-12-06 2011-12-28 琳得科株式会社 可食性薄膜

Also Published As

Publication number Publication date
IL239279A0 (en) 2015-07-30
SG11201504461QA (en) 2015-07-30
CN104869984A (zh) 2015-08-26
EP2934493A1 (en) 2015-10-28
US20150328277A1 (en) 2015-11-19
KR20150111919A (ko) 2015-10-06
EP2934493A4 (en) 2016-09-07
WO2014100643A8 (en) 2015-06-25
HK1214133A1 (zh) 2016-07-22
HK1214522A1 (zh) 2016-07-29
ZA201505050B (en) 2016-10-26
CA2895457A1 (en) 2014-06-26
EA201591187A1 (ru) 2016-03-31
MX2015007794A (es) 2015-09-04
WO2014100643A1 (en) 2014-06-26
JP2016503066A (ja) 2016-02-01
AU2013361057A1 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
BR112015031903A2 (pt) composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto
BR112014011841A2 (pt) material de entrega de fármacos hidrofóbicos, método para a produção do mesmo e métodos para a entrega de uma composição de entrega de fármacos
EA201690107A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
BR112014016668A8 (pt) composições para cuidados pessoais contendo silicone iônico e agente formador de filme
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
MX348823B (es) Formulaciones estables de linaclotida.
BR112015004185A2 (pt) composições antiperspirantes em aerossol, produtos e métodos
BR112012026596A2 (pt) método para preparar composições farmacêuticas pretendidas para administração oral compreendendo um ou mais ingredientes ativos e as composições que compreendem as mesmas
BR112015014092A2 (pt) administração oral transmucosal de acetato de glatirâmer
EA201270741A1 (ru) Пероральные композиции и липофильные соли метилналтрексона
BR112012019997A2 (pt) composições de cuidado oral
BR112013020537A2 (pt) suspensão aquosa e pó de liberação prolongada que compreendem metilfenidato
BR112015014095A2 (pt) entrega transmucosal de acetato de glatirâmero
BR112015014480A2 (pt) composições estáveis contendo íons metálicos
MX2022001144A (es) Metodos y composiciones para modular la microbiota intestinal y para manejar el peso.
PH12014502366B1 (en) Injectable formulation
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
PH12015502632A1 (en) Cxcr7 receptor modulators
UY33568A (es) Compuestos que interactuan con proteina reguladora de glucocinasa para el tratamiento de diabetes.
TR201004464A2 (tr) Kemik erimesi için formülasyon.
BR112015000275A2 (pt) utilização de um extrato de mirta como agente anti-biopelícula face p. acnes
BR112014016450A2 (pt) composto antagonista de leucotrieno b4
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2495 DE 30-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.